厄贝沙坦联合美托洛尔治疗慢性充血性心衰患者的临床分析

Clinical Analysis of Irbesartan Combined with Metoprolol for the Treatment of Chronic Congestive Heart Failure

目的探讨厄贝沙坦联合美托洛尔治疗慢性充血性心衰患者的临床效果。方法选择我院2013年1月至2014年1月期间收治的82例慢性充血性心衰患者作为研究对象,随机分为传统治疗组和联合治疗组各41例。传统治疗组按照传统标准治疗方案给予强心、利尿及扩血管等基础治疗,联合治疗组在此基础上加用厄贝沙坦联合美托洛尔治疗,比较两组的临床治疗效果。结果治疗后,联合治疗组的总有效率为90.24%,明显高于传统治疗组的70.73%,组间差异有统计学意义(P<0.05)。治疗后,与传统治疗组相比,联合治疗组的LVEF上升趋势、LVEDd和LVESd下降趋势更显著,组间比较差异有统计学意义(P<0.05)。结论厄贝沙坦联合美托洛尔治疗慢性充血性心衰效果显著,安全可靠,值得临床推广。

Objective To explore the clinical effect of irbesartan combined with metoprolol for the treatment of chronic congestive heart failure. Methods Eighty-two cases of patients with chronic congestive heart failure admitted to our hospital from January 2013 to January 2014 were selected and randomly divided into two groups equally. The tradition group received traditional standard treatment including strengthening heart, diuretic and vasodilator therapy, while the combined group received irbesartan combined with metoprolol therapy on the basis of traditional standard treatment. The clinical effects of two groups were compared. Results The total effective rate of combined group was 90.24%, significantly higher than 70.73% of control group（P〈0.05）. After treatment, compared with traditional group,the combined group had more significant increase of LVEF, and decrease of LVEDd and LVESd, and the differences between two groups were statistically significant（P〈0.05）. Conclusions Irbesartan combined with metoprolol for the treatment of chronic congestive heart failure has significant efficacy and safety, which is worthy of clinical promotion.